AEON Biopharma, Inc. (AEON)
Company Description
AEON Biopharma is a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions.
ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus, Inc under the name Jeuveau. Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States.
Our initial development programs for ABP-450 are directed at migraine, cervical dystonia and gastroparesis. Our Investigational New Drug application for ABP-450 as a preventative treatment for migraine was accepted by the FDA in the fourth quarter of 2020 and we initiated enrolling patients for our Phase 2 clinical study in the first quarter of 2021.
We plan to announce topline data related to our migraine study in the second half of 2022. Our IND application for ABP-450 as a treatment for cervical dystonia was accepted by the FDA in the third quarter of 2020 and we initiated our Phase 2 clinical study in the first quarter of 2021.
We plan to announce topline data in early 2022. In December 2020, we initiated a preclinical gastroparesis study. We expect to complete this preclinical study in the third quarter of 2021.
| Country | United States |
| Founded | 2012 |
| Industry | Pharmaceutical Preparations |
| Sector | Biotechnology |
| Employees | 6 |
| CEO | Marc Forth |
Contact Details
Address:
4040 MacArthur Blvd., Suite 260 Newport Beach, CA 92660 United States | |
| Phone | (949) 354-6499 |
| Website | aeonbiopharma.com |
Stock Details
| Ticker Symbol | AEON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1622667 |
Key Executives
| Name | Position |
|---|---|
| Marc Forth | Chief Executive Officer and Director Nominee |
| Chris Carr | Chief Financial Officer |
| Chad Oh, M.D. | Chief Medical Officer |
| Simone Blank | Director, Chair |
| Jost Fischer | Director, Chairman Elect |
| Robert E. Grant | Director |
| Vikram Malik | Director |
| Darren O\'Brien | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 29, 2021 | RW | Registration Withdrawal Request |
| Oct 7, 2021 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Oct 6, 2021 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Oct 4, 2021 | S-1/A | General form for registration of securities under the Securities Act of 1933 |
| Sep 17, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 13, 2021 | DRS/A | Draft Registration Statement |
| Jul 20, 2021 | DRS/A | Draft Registration Statement |
| Jun 7, 2021 | DRS/A | Draft Registration Statement |
| May 13, 2021 | D/A | Notice of Exempt Offering of Securities |
| Aug 31, 2020 | D | Notice of Exempt Offering of Securities |